On the 30th June 2020, Regulis Consulting Limited merged with the PharmaLex Group.
PharmaLex is a leading provider of specialised services for the pharma, biotech and medical device industries worldwide. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis and brings real mutual benefits.
By joining forces with PharmaLex, Regulis will strengthen its European and Global strategic and operational capabilities to ensure we help clients effectively navigate the regulatory maze to:
- Get their products licensed and to market as quickly and efficiently as possible.
- Enhance the value of their products with seamless compliance.
- Protect their patients and the value of their products.
As part of PharmaLex Group, with an expanded knowledge, expertise and passion for what we do, we will continue to increase revenue, decrease risk and reduce costs for clients across the globe. “Our services in Regulatory Affairs, Pharmacovigilance and Quality Assurance align perfectly within the PharmaLex portfolio. Becoming part of a larger organisation with an excellent reputation and significant global footprint is an exciting step for Regulis and our clients”, explained Kim Wharton, Founder and Managing Director, Regulis.